查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1646787

全球单核细胞活化试验 (MAT) 市场

Monocyte Activation Tests (MAT)
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 244 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球单核球活化试验 (MAT) 市场规模将达到 2.855 亿美元

2024 年全球单核细胞活化试验 (MAT) 市场规模估计为 9,470 万美元，预计到 2030 年将达到 2.855 亿美元，2024-2030 年分析期内的复合年增长率为 20.2%。 MAT套件是报告中分析的细分市场之一，预计到分析期结束时复合年增长率为 18.5%，达到 1.572 亿美元。在分析期内，MAT 试剂部分的成长率预计将达到 22.5% 的复合年增长率。

美国市场规模估计为 2,520 万美元，中国市场预计复合年增长率为 19.0%

预计到 2024 年美国核细胞活化测试 (MAT) 市场价值将达到 2,520 万美元。中国是世界第二大经济体，预计到 2030 年市场规模将达到 4,340 亿美元，2024 年至 2030 年的复合年增长率为 19.0%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为 18.3% 和 17.5%。在欧洲，德国的复合年增长率预计为 15.0%。

全球单核细胞活化测试市场 - 主要趋势与驱动因素摘要

什么是单核细胞活化试验 (MAT)？

单核细胞活化试验 (MAT) 是一种检测药品、医疗设备和生物製药中是否存在热原的体外检测方法。这些测试利用人类单核细胞或单核细胞系，在暴露于热原时释放促炎细胞激素，如 IL-6 和 TNF-α。 MAT 是传统兔热原试验 (RPT ) 和鲎变形细胞裂解物 (LAL) 测试的可靠替代方案，可确保注射药物、疫苗、静脉注射液和植入式医疗设备。

单核细胞活化测试的重要性在于其准确性、与人类的相关性以及检测内毒素和非内毒素热原的能力。与仅检测内毒素的 LAL 检测不同，MAT 可以识别更广泛的热原，确保对药物和医疗设备进行全面的安全评估。 MAT 符合 3R （替代、减少、改进）原则，旨在尽量减少在测试中使用动物。这使得 MAT 不仅能有效检测热原，而且在道德上符合安全测试方面的最新监管要求和行业标准。

技术进步如何影响单核细胞活化测试市场？

技术进步显着提高了单核细胞活化测试的效率、灵敏度和可重复性，促进了药物安全测试的创新。一项重大进展是使用冷冻保存的人类单核细胞，这提高了 MAT 的一致性和可用性。冷冻保存的细胞提供了标准化、即用型测试解决方案，减少了结果的差异性并提高了不同实验室的可重复性。这些进步使得 MAT 更容易取得，特别是在新血供应有限或不切实际的环境中。

自动化 MAT 平台的发展使得热原测试更具扩充性和效率。自动化系统简化了从样品准备到资料分析的整个测试过程，减少了人工错误并提高了吞吐量。自动化使 MAT 更适合生物製药製造中的大规模筛检，因为该领域需要进行大量测试以确保产品安全。此外，使用高通量筛检(HTS)技术可以快速识别热原，支援在药物开发和批量发布期间进行快速安全评估。

细胞激素检测和即时PCR等分析技术的进步提高了 MAT 的灵敏度和准确性。这些技术可以同时测量多种细胞激素，从而提供更全面的热原活性概况。与先进的资料分析和人工智慧 (AI) 工具的整合进一步改善了对 MAT 结果的解释，从而能够在产品安全评估中做出更快、更准确的决策。这些创新不仅扩展了单核细胞活化测试的能力，而且符合药物安全测试的自动化、提高灵敏度和道德测试的更广泛趋势。

单核细胞活化试验在各领域有哪些新的应用？

由于生物製药、医疗设备和疫苗对可靠、道德和全面的热原检测的需求，单核细胞活化测试在各个领域的应用越来越广泛。在生物製药领域，MAT 广泛用于测试注射药物，包括单株抗体、重组蛋白以及细胞和基因疗法等生技药品。 MAT 检测内毒素和非内毒素热原的能力对于确保这些复杂生物製药的安全至关重要，而传统的 LAL 测试可能会遗漏某些污染物。

在疫苗产业，MAT 在确保疫苗安全方面发挥关键作用，尤其是采用 mRNA 和病毒载体等现代方法开发的疫苗。鑑于快速开发和大规模生产的需求，MAT 提供了一种可靠的、非动物源的替代方案，可纳入疫苗品管流程。 MAT 特别适用于检测新疫苗製剂中的热原，例如在 COVID-19 大流行期间开发的疫苗製剂，其中快速、合乎道德和准确的测试至关重要。

在医疗设备产业，MAT 用于检测植入装置、透析液和输液中的热原污染物。由于医疗设备经常与体液直接接触，因此必须进行严格的热原测试，以防止产生不良的免疫反应。 MAT 对这些医疗设备提供了更全面的安全评估，支援法规遵循并提高病患安全。在化妆品领域，MAT 用于评估注射化妆品（如真皮填充剂）的安全性，以确保它们不含有害的热原。

在研发领域，MAT 在药物和产品开发的早期阶段的应用越来越多。在临床前试验中使用 MAT 可让研究人员在开发过程的早期识别和消除致热风险，从而提高获得监管部门核准的机会并降低后期失败的成本。 MAT 在这些领域的应用不断扩大，凸显了其在提高安全性、支持伦理试验以及简化药品、医疗设备及相关产品的品管方面发挥的重要作用。

是什么推动了单核细胞活化测试市场的成长？

单核细胞活化测试 (MAT) 市场的成长受到多种因素的推动，例如对全面热原测试的需求不断增加、对道德测试方法的采用日益增多以及生物製药开发的进步。主要成长要素之一是向非动物测试方法的转变。随着 FDA 和 EMA 等监管机构推动采用符合 3R 原则的体外方法，MAT 正逐渐成为一种有效的替代动物热原测试方法，例如兔热原测试 (RPT)。监管部门对伦理测试的推动正在加速 MAT 在製药和医疗设备製造领域的应用。

生物製药和先进疗法的日益复杂性进一步推动了对 MAT 的需求。生技药品、生物相似药、细胞和基因疗法以及 mRNA 疫苗的兴起推动了对能够检测一系列热原的安全测试的需求。 MAT 能够识别内毒素和非内毒素热原，因此成为传统内毒素检测可能不足的先进疗法的首选。

自动化、高通量筛检和冷冻保存细胞技术的进步也促进了 MAT 市场的成长。自动化和高通量能力使 MAT 更具可扩展性和高效性，支援其在大规模生物製药生产和批量放行测试中的使用。冷冻保存单核细胞的使用使得 MAT 更加可靠、更少变化，并且更易于在不同实验室中常规使用。

製药和医疗设备业严格的安全法规和品质控制标准进一步推动了 MAT 的采用。全面的热原检测的监管要求使得製造商必须实施严格的安全测试通讯协定。 MAT 不仅符合这些监管要求，还提供了一种更快速、更可靠、更符合道德的热原检测方法，使其成为现代安全评估策略的关键组成部分。

由于细胞化验分析技术的不断创新、体外测试的监管支援以及生物製药的日益复杂性，MAT 市场有望实现强劲成长。这些趋势，加上对可靠、全面和道德的热原检测的日益增长的需求，使得 MAT 成为广泛领域的药品品管、生物製药开发和法规遵循的重要组成部分。

部分

产品类型（MAT套件、MAT 试剂）、来源（基于週边血单核细胞 (PBMC)、基于细胞株）、最终用途（製药最终用途、生物技术最终用途、医疗设备最终用途、其他最终用途）

受访企业范例（共41家）

  • Becton, Dickinson & Company
  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Microcoat Biotechnologie GmbH
  • Sanquin
  • Solvias AG
  • Thermo Fisher Scientific, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP16601

Global Monocyte Activation Tests (MAT) Market to Reach US$285.5 Million by 2030

The global market for Monocyte Activation Tests (MAT) estimated at US$94.7 Million in the year 2024, is expected to reach US$285.5 Million by 2030, growing at a CAGR of 20.2% over the analysis period 2024-2030. MAT Kits, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$157.2 Million by the end of the analysis period. Growth in the MAT Reagents segment is estimated at 22.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.2 Million While China is Forecast to Grow at 19.0% CAGR

The Monocyte Activation Tests (MAT) market in the U.S. is estimated at US$25.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$43.4 Million by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.3% and 17.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global Monocyte Activation Tests Market - Key Trends & Drivers Summarized

What Are Monocyte Activation Tests (MAT), and Why Are They So Crucial in Modern Biopharmaceutical Safety?

Monocyte Activation Tests (MAT) are in-vitro assays that detect the presence of pyrogens—fever-inducing substances, in pharmaceutical products, medical devices, and biologicals. These tests utilize human monocytes or monocytic cell lines, which, upon exposure to pyrogens, release pro-inflammatory cytokines like IL-6 and TNF-α. MAT offers a reliable alternative to traditional rabbit pyrogen tests (RPT) and Limulus Amebocyte Lysate (LAL) tests, making it a critical tool in ensuring the safety and quality of injectable drugs, vaccines, intravenous solutions, and implantable medical devices.

The importance of monocyte activation tests lies in their accuracy, human relevance, and ability to detect both endotoxins and non-endotoxin pyrogens. Unlike LAL tests, which only detect endotoxins, MAT can identify a broader spectrum of pyrogens, ensuring comprehensive safety assessments for pharmaceuticals and medical devices. MAT is aligned with the principles of the 3Rs (Replacement, Reduction, Refinement), which aim to minimize the use of animals in testing. This makes MAT not only effective in detecting pyrogens but also ethically aligned with modern regulatory requirements and industry standards in safety testing.

How Are Technological Advancements Shaping the Monocyte Activation Tests Market?

Technological advancements have significantly enhanced the efficiency, sensitivity, and reproducibility of Monocyte Activation Tests, driving innovation in pharmaceutical safety testing. One of the major developments is the use of cryopreserved human monocytes, which have improved the consistency and availability of MAT. Cryopreserved cells provide standardized and ready-to-use testing solutions, reducing variability in test results and improving reproducibility across different laboratories. This advancement has made MAT more accessible, especially in settings where fresh blood supply is limited or impractical.

The development of automated MAT platforms has further improved the scalability and efficiency of pyrogen testing. Automated systems streamline the entire testing process, from sample preparation to data analysis, reducing manual errors and enhancing throughput. Automation has made MAT more suitable for large-scale screening in biopharmaceutical manufacturing, where high-volume testing is required to ensure product safety. Additionally, the use of high-throughput screening (HTS) technologies has enabled faster identification of pyrogens, supporting rapid safety assessments during drug development and batch release.

Advancements in analytical techniques, such as multiplex cytokine assays and real-time PCR, have increased the sensitivity and accuracy of MAT. These techniques allow for the simultaneous measurement of multiple cytokines, providing a more comprehensive profile of pyrogenic activity. Integration with advanced data analytics and artificial intelligence (AI) tools has further improved the interpretation of MAT results, enabling faster and more precise decision-making in product safety evaluations. These technological innovations not only expand the capabilities of monocyte activation tests but also align with broader trends toward automation, higher sensitivity, and ethical testing in pharmaceutical safety.

What Are the Emerging Applications of Monocyte Activation Tests Across Different Sectors?

Monocyte Activation Tests are finding expanding applications across various sectors, driven by the need for reliable, ethical, and comprehensive pyrogen detection in biopharmaceuticals, medical devices, and vaccines. In the biopharmaceutical sector, MAT is widely used for testing injectable drugs, including biologics like monoclonal antibodies, recombinant proteins, and cell or gene therapies. The ability of MAT to detect both endotoxin and non-endotoxin pyrogens is critical for ensuring the safety of these complex biological products, where traditional LAL tests may miss certain contaminants.

In the vaccine industry, MAT plays a vital role in ensuring the safety of vaccines, particularly those developed through modern methods like mRNA or viral vectors. Given the need for rapid development and mass production, MAT offers a reliable, non-animal-based alternative that can be integrated into vaccine quality control pipelines. It is particularly valuable in detecting pyrogens in new vaccine formulations, such as those developed during the COVID-19 pandemic, where rapid, ethical, and accurate testing was essential.

In the medical device industry, MAT is used to test implantable devices, dialysis fluids, and intravenous solutions for pyrogenic contaminants. Since medical devices often come into direct contact with body fluids, rigorous pyrogen testing is necessary to prevent adverse immune reactions. MAT provides a more comprehensive safety assessment for these devices, supporting regulatory compliance and improving patient safety. In the cosmetic sector, MAT is used to evaluate the safety of injectable cosmetic products like dermal fillers, ensuring they are free from harmful pyrogens.

In research and development, MAT is increasingly employed during the early stages of drug and product development. Its use in preclinical testing allows researchers to identify and eliminate pyrogenic risks early in the development process, improving the likelihood of regulatory approval and reducing costs associated with late-stage failures. The expanding applications of MAT across these sectors highlight its critical role in enhancing safety, supporting ethical testing, and improving efficiency in the quality control of pharmaceuticals, medical devices, and related products.

What Drives Growth in the Monocyte Activation Tests Market?

The growth in the Monocyte Activation Tests (MAT) market is driven by several factors, including increasing demand for comprehensive pyrogen testing, rising adoption of ethical testing methods, and advancements in biopharmaceutical development. One of the primary growth drivers is the shift toward non-animal testing methods. As regulatory agencies like the FDA and EMA promote the adoption of in-vitro methods aligned with the 3Rs principles, MAT has gained traction as an effective alternative to animal-based pyrogen tests like the rabbit pyrogen test (RPT). This regulatory push toward ethical testing has accelerated the adoption of MAT in pharmaceutical and medical device manufacturing.

The growing complexity of biopharmaceuticals and advanced therapies has further fueled demand for MAT. With the rise of biologics, biosimilars, cell and gene therapies, and mRNA vaccines, there is a greater need for safety tests that can detect a wide range of pyrogens. MAT’s ability to identify both endotoxin and non-endotoxin pyrogens makes it a preferred choice for these advanced therapies, where traditional endotoxin tests may be insufficient.

Advancements in automation, high-throughput screening, and cryopreserved cell technology have also contributed to the growth of the MAT market. Automation and high-throughput capabilities have made MAT more scalable and efficient, supporting its use in large-scale biopharmaceutical production and batch release testing. The availability of cryopreserved monocytes has improved MAT’s reliability, reducing variability and making it more practical for routine use across different testing sites.

Stringent safety regulations and quality control standards in the pharmaceutical and medical device industries have further driven the adoption of MAT. Regulatory requirements for comprehensive pyrogen testing have made it essential for manufacturers to implement robust safety testing protocols. MAT not only meets these regulatory requirements but also offers a faster, more reliable, and ethical approach to pyrogen detection, making it a key component of modern safety assessment strategies.

With ongoing innovations in cell-based assays, regulatory support for in-vitro testing, and the growing complexity of biopharmaceutical products, the MAT market is poised for robust growth. These trends, combined with increasing demand for reliable, comprehensive, and ethical pyrogen detection, make MAT a vital component of pharmaceutical quality control, biopharmaceutical development, and regulatory compliance across various sectors.

SCOPE OF STUDY:

The report analyzes the Monocyte Activation Tests (MAT) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (MAT Kits, MAT Reagents); Source (Peripheral Blood Mononuclear Cell (PBMC) Based, Cell Line Based); End-Use (Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Becton, Dickinson & Company
  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Microcoat Biotechnologie GmbH
  • Sanquin
  • Solvias AG
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Monocyte Activation Tests - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Need for Pyrogen Testing Drives Demand for Monocyte Activation Tests
    • Increasing Focus on Patient Safety in Drug Development Sets the Stage for Market Growth
    • Strong Regulatory Support for Safer Drug Testing Strengthens Business Case
    • Growing Use in Biopharmaceutical Production Expands Addressable Market
    • Growing Role in Quality Control Generates Demand in Pharmaceutical Industry
    • Increasing Focus on Animal-free Testing Drives Adoption of Monocyte Activation Tests
    • Expanding Use in Vaccine Safety Testing Sets the Stage for Market Expansion
    • Rising Focus on Endotoxin-free Manufacturing Generates Demand
    • Use in Cell Therapy Development Propels Monocyte Activation Test Market
    • Increasing Applications in Oncology and Immunotherapy Strengthen Market Position
    • Growing Role in Risk Assessment for Blood Products Drives Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Monocyte Activation Tests (MAT) Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Monocyte Activation Tests (MAT) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for MAT Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for MAT Kits by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for MAT Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for MAT Reagents by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Peripheral Blood Mononuclear Cell (PBMC) Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Peripheral Blood Mononuclear Cell (PBMC) Based by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cell Line Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Cell Line Based by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharmaceutical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharmaceutical End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biotechnology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Biotechnology End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Medical Device End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Medical Device End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION